Clinical trials: Left Heart Failure
Heart Failure
Impact of Cardiac Resynchronization Therapy on Right Ventricular Function in Left Ventricular Assist Device Patients
Left Ventricular Assist Devices (LVAD) are mechanical heart pumps that are increasingly being implanted in patients with severe heart failure which have failed medical therapy.
- Trial name
- CRT-LVAD (NCT02169076)
- Testing
- Cardiac Resynchronization Therapy
- Where
- United States
- Sponsor
- University of Louisville
End-stage Heart Failure
Long-Term Survival After LVAD Implantation in End-Stage Heart Failure
This is a prospective, observational, multi-center cohort study designed to evaluate long-term survival and clinical outcomes in patients with end-stage heart failure undergoing left ventricular assist device (LVAD) implantation.
- Trial name
- NCT07382284
- Testing
- Left Ventricular Assist Device (LVAD) implantation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Heart Failure
Promote Q Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Quartet Left Ventricular Heart Lead Study
The objective of this study is to assess the safety and efficacy of the Quartet™ lead and Promote Q® device system in a patient population indicated for cardiac resynchronization therapy.
- Trial name
- Promote Q (NCT00990665)
- Testing
- CRT-D and LV lead (Quartet™ lead and Promote Q® device system)
- Where
- 24 sites in United States
- Volunteers
- 178 people
- Sponsor
- Abbott Medical Devices
Children, Chronic Renal Failure
Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients
In children with chronic kidney disease, progression to end-stage renal failure is associated with high patient morbidity and poor quality of life.
- Conditions
- Children, Chronic Renal Failure, Hypertension, Acquired Kidney Disease
- Trial name
- ESCAPE (NCT00221845)
- Testing
- ACE Inhibition, Intensified Blood Pressure Control, Add-on Angiotensin Receptor Blockade
- Where
- 33 sites in Czechia, France and 10 more
- Volunteers
- 400 people
- Sponsor
- Heidelberg University
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure
Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells
This is a pilot study comparing the effect of intra-coronary versus intramyocardial application of enriched CD133pos autologous bone marrow derived stem cells for improving left ventricular function in chronic ischemic…
- Trial name
- AlsterMACS (NCT01337011)
- Testing
- autologous CD133pos stem cell application
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Asklepios proresearch
Heart Failure
Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) Therapy
Cardiac resynchronization therapy (CRT) or biventricular pacing is a useful treatment for heart failure and those suffering from arrhythmias.
- Trial name
- NCT02083419
- Testing
- LVAD CRT
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Heart Failure, Left-sided, Anemia, Iron Deficiency
ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure (ORION-HF)
This is an open-label, single arm, multicenter pilot-study to explore the safety, tolerability and efficacy of oral iron supplementation with ferric maltol in treating iron deficiency and anaemia in patients with heart failure.
- Trial name
- NCT05697211
- Testing
- Ferric maltol 30 mg (Feraccru®)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Hannover Medical School
Pulmonary Hypertension Due to Left Heart Disease, Heart Failure With Preserved Ejection Fraction
Training in HFpEF-PH
Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved…
- Trial name
- TRAIN HFpEF (NCT05464238)
- Testing
- Exercise rehabilitation, Standard treatment
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 90 people
- Sponsor
- Heidelberg University
HFrEF - Heart Failure With Reduced Ejection Fraction, HFmrEF
Coffee Use, Physical Activity and Symptomatic Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction and an ICD
The goal of this observational study is to learn whether caffeine consumption is associated with ventricular arrhythmias and physical activity in adults with heart failure, reduced left ventricular ejection fraction, and an…
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFmrEF, Ventricular Arrhythmia, ICD
- Trial name
- CUPS-ICD (NCT07823998)
- Testing
- Questionnaire
- Where
- Belgium
- Volunteers
- 170 people
- Sponsor
- Jean-Benoît Le Polain de Waroux
Congestive Heart Failure
Stimulus Intensity in Left Ventricular Leads
Cardiac resynchronization therapy (CRT) is a device implanted to improve the function of some people's hearts. CRT involves the placement of 3 wires in the heart through a vein near the front of your left or right shoulder into…
- Trial name
- SILVeR-CRT (NCT01060449)
- Testing
- LV stimulus intensity
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Left Ventricular Dysfunction, Cardiac Conduction Defect
Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum
Cardiac pacing is the only effective treatment for symptomatic bradycardia. The right ventricular apex (RVA) has become the most frequently used ventricular pacing site.
- Conditions
- Left Ventricular Dysfunction, Cardiac Conduction Defect, Heart Failure, Sick Sinus Syndrome
- Trial name
- NCT01609738
- Testing
- Left ventricular septum pacing lead
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Maastricht University Medical Center
Pulmonary Hypertension
Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure
A number of 100 patients with pulmonary hypertension associated with the left Heart failure scheduled for elective pulmonary arterial denervation (PADN) are randomized 1:1 to either PADN or control group.
- Trial name
- PADN-5 (NCT02220335)
- Testing
- Pulmonary arterial denervation, Standard treatment
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Heart Failure
Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System
This is a prospective, multi-center, unblinded, randomized, controlled, and non-inferiority study comparing the EVA2 LVAS to the most recent magnetically levitated centrifugal LVAS (HM3 LVAS).
- Trial name
- COMPETENCE (NCT01187368)
- Testing
- EVAHEART Left Ventricular Assist System (LVAS), HeartMate 3
- Where
- 12 sites in United States
- Volunteers
- 399 people
- Sponsor
- Evaheart, Inc.
Anterior Myocardial Infarction, Heart Failure
RIGENERA 2.0 Trial
Study Objectives: To determine whether, in patients with large acute myocardial infarction undergoing primary or rescue angioplasty, the administration of subcutaneous Lenograstim [recombinant human Granulocyte-Colony Stimulating…
- Trial name
- RIGENERA (NCT02502747)
- Testing
- rhu G-CSF, optimal standard of care, Myocardial Contrast Echocardiography
- Where
- Italy
- Sponsor
- Catholic University of the Sacred Heart
Myocardial Infarct, Remodeling, Left Ventricle
Heart Attack Blood Oxygen Therapy Trial
'Heart attack', known as acute ST-segment elevation myocardial infarction, is a leading cause of heart failure and death. A lack of blood and oxygen damages the heart muscle potentially causing heart failure and premature death.
- Trial name
- SSO2 Radial MI (NCT06662890)
- Testing
- Supersaturated oxygen
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- NHS National Waiting Times Centre Board
Diastolic Function
Determination of Diastolic Dysfunction by Single Lead Electrocardiogram
It is a prospective, controlled, single-center, non-randomized, observational study. From September 2019 to December 2020, the study plans to prospectively include 400 patients aged 18 to 90 years.
- Trial name
- NCT04474639
- Testing
- echocardiographic examination
- Where
- Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Dilated Cardiomyopathy
Effect of Rosuvastatin on Left Ventricular Remodeling
The purpose of this study is to examine the the effect of the HMG-CoA reductase inhibitor Rosuvastatin on left ventricular remodeling in patients with dilated cardiomyopathy.
- Trial name
- NCT00505154
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 75 people
- Sponsor
- Oslo University Hospital
Heart Failure，Congestive, Heart Failure New York Heart Association Class IV
Nicotinamide Riboside in LVAD Recipients
While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR…
- Conditions
- Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
- Trial name
- PilotNR-LVAD (NCT03727646)
- Testing
- Nicotinamide riboside
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Heart Failure
BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally
- Trial name
- ARTS (NCT01345656)
- Testing
- BAY94-8862, Spironolactone
- Where
- 50 sites in Austria, Belgium and 8 more
- Volunteers
- 457 people
- Sponsor
- Bayer